분자 종양 진단 시장 : 전략적 인사이트와 예측(2026-2035년)

The Molecular Oncology Diagnostics Market is expected to grow at a CAGR of 9.2% from a market value of USD 4.75 billion in 2026 to USD 10.51 billion in 2035.

The global molecular oncology diagnostics market is experiencing rapid growth as precision medicine transforms cancer diagnosis and treatment. Molecular oncology diagnostics utilize advanced genomic and molecular technologies to identify genetic mutations, biomarkers, gene expression patterns, and other molecular alterations associated with various cancers. These diagnostic approaches enable clinicians to detect cancer at earlier stages, select targeted therapies, monitor disease progression, assess treatment response, and identify recurrence with greater accuracy than conventional diagnostic methods. The increasing global burden of cancer, growing adoption of personalized medicine, and continuous advancements in genomic technologies are driving strong demand for molecular oncology diagnostic solutions.

The market includes molecular diagnostic instruments, reagents, assay kits, software, sequencing platforms, companion diagnostics, and laboratory services. Continuous innovation in next-generation sequencing (NGS), polymerase chain reaction (PCR), digital PCR, fluorescence in situ hybridization (FISH), liquid biopsy, and multiplex molecular assays has significantly improved analytical sensitivity, turnaround time, and clinical utility. These technologies enable comprehensive genomic profiling of tumors while supporting individualized treatment planning and improved patient outcomes.

Growing adoption of targeted therapies has significantly increased the importance of molecular diagnostics in oncology. Pharmaceutical companies increasingly require companion diagnostic tests to identify patients most likely to benefit from specific cancer therapies. In addition, expanding applications of liquid biopsy for non-invasive cancer detection and disease monitoring are reshaping clinical practice by reducing dependence on surgical tissue biopsies. Increasing investment in cancer research, favorable regulatory support for precision medicine, and expanding reimbursement coverage in several developed markets continue to strengthen industry growth.

Healthcare providers worldwide are modernizing laboratory infrastructure and integrating molecular testing into routine oncology care. Academic research institutions, biotechnology companies, pharmaceutical manufacturers, and contract research organizations are also increasing utilization of molecular oncology diagnostics for biomarker discovery, clinical trial patient selection, and therapeutic monitoring. As genomic medicine continues to advance, molecular oncology diagnostics are expected to become an essential component of comprehensive cancer management throughout the forecast period.

Market Drivers

Rising Global Cancer Burden

The increasing incidence of breast cancer, lung cancer, colorectal cancer, prostate cancer, hematological malignancies, and other solid tumors is driving demand for highly accurate molecular diagnostic technologies. Early molecular diagnosis supports timely treatment initiation and improves survival outcomes.

Growing Adoption of Precision Medicine

Healthcare providers are increasingly utilizing genomic information to personalize cancer treatment. Molecular diagnostics enable identification of actionable genetic mutations, allowing clinicians to select targeted therapies based on individual tumor biology.

Advancements in Genomic Technologies

Continuous improvements in next-generation sequencing, digital PCR, liquid biopsy, multiplex molecular testing, and bioinformatics are enhancing diagnostic accuracy, reducing testing time, and expanding clinical applications.

Expansion of Companion Diagnostics

The growing pipeline of targeted oncology therapies has increased demand for companion diagnostic tests that identify eligible patient populations and improve treatment outcomes.

Increasing Investments in Oncology Research

Governments, biotechnology companies, pharmaceutical manufacturers, and research institutions continue to invest heavily in cancer genomics, biomarker discovery, and molecular medicine, supporting long-term market growth.

Market Restraints

High Cost of Molecular Testing

Advanced molecular diagnostic platforms and comprehensive genomic profiling remain expensive, limiting adoption in healthcare systems with constrained financial resources.

Complex Regulatory Requirements

Molecular diagnostic products require extensive clinical validation and regulatory approval, increasing development costs and extending commercialization timelines.

Limited Access in Developing Regions

Many healthcare facilities in low- and middle-income countries lack the laboratory infrastructure, specialized equipment, and trained personnel necessary for advanced molecular testing.

Data Interpretation Challenges

Comprehensive genomic profiling generates large volumes of complex molecular data that require advanced bioinformatics tools and highly trained specialists for accurate interpretation.

Reimbursement Variability

Differences in reimbursement policies across countries continue to affect accessibility and routine clinical adoption of advanced molecular oncology diagnostics.

Technology and Segment Insights

The molecular oncology diagnostics market can be segmented by product, technology, application, cancer type, end user, and geography.

By Product

Reagents and assay kits account for the largest share of the market because they are required for every molecular diagnostic test. Continuous growth in testing volumes generates recurring demand for high-quality reagents, primers, probes, controls, and sequencing consumables.

Diagnostic instruments continue to experience strong growth as laboratories invest in automated sequencing systems, PCR platforms, digital PCR instruments, and integrated molecular diagnostic analyzers.

Software and bioinformatics platforms are becoming increasingly important for genomic data analysis, variant interpretation, laboratory workflow management, and clinical reporting.

By Technology

Next-generation sequencing represents one of the fastest-growing technology segments because it enables comprehensive genomic profiling, mutation detection, and precision oncology applications.

Polymerase chain reaction remains widely utilized due to its speed, accuracy, affordability, and broad applicability across oncology diagnostics.

Digital PCR continues to gain importance for highly sensitive mutation detection and minimal residual disease monitoring.

Fluorescence in situ hybridization, microarray technologies, and liquid biopsy platforms continue to expand their role in comprehensive molecular cancer diagnostics.

By Application

Cancer diagnosis remains the largest application segment as molecular diagnostics support early detection, accurate tumor classification, and disease staging.

Companion diagnostics represent a rapidly expanding segment driven by increasing approval of targeted oncology therapies.

Treatment monitoring and recurrence detection continue to gain momentum as clinicians increasingly utilize circulating tumor DNA and molecular biomarkers to evaluate therapeutic response.

Research applications also contribute significantly through biomarker discovery, clinical trials, translational medicine, and pharmaceutical development.

By Cancer Type

Lung cancer represents a major application area due to widespread use of EGFR, ALK, ROS1, KRAS, and other biomarker testing.

Breast cancer continues to generate substantial demand through HER2, BRCA, and genomic expression profiling.

Colorectal, prostate, hematological, ovarian, melanoma, and other cancers increasingly rely on molecular diagnostics to support personalized treatment selection.

By End User

Hospitals represent the largest end-user segment because of increasing integration of molecular diagnostics into routine oncology care.

Independent diagnostic laboratories continue to strengthen market demand by providing specialized genomic testing services.

Academic research institutes, biotechnology companies, pharmaceutical organizations, and contract research organizations extensively utilize molecular diagnostics for oncology research and drug development.

By Geography

North America dominates the market owing to advanced healthcare infrastructure, widespread adoption of precision medicine, strong reimbursement systems, and significant investment in cancer genomics.

Europe continues to experience steady growth supported by established oncology care networks, expanding genomic medicine initiatives, and increasing healthcare investments.

Asia Pacific is expected to witness the fastest growth due to rising cancer incidence, expanding healthcare infrastructure, increasing government investment in precision medicine, and improving access to advanced molecular diagnostics.

Latin America and the Middle East & Africa are gradually strengthening their molecular diagnostic capabilities through healthcare modernization and laboratory expansion initiatives.

Competitive and Strategic Outlook

The competitive landscape includes molecular diagnostics companies, biotechnology firms, genomic sequencing providers, medical device manufacturers, pharmaceutical companies, and healthcare technology organizations. Competition is centered on improving analytical accuracy, expanding biomarker panels, increasing laboratory automation, enhancing bioinformatics capabilities, and developing integrated precision oncology solutions.

Manufacturers continue to invest in next-generation sequencing platforms, liquid biopsy technologies, artificial intelligence-enabled genomic analysis, digital pathology integration, and companion diagnostics. Strategic collaborations between pharmaceutical companies and diagnostic manufacturers are accelerating biomarker validation and expanding the availability of targeted cancer therapies. Product launches, acquisitions, research partnerships, regulatory approvals, and international expansion remain key strategies for strengthening market position.

Conclusion

The global molecular oncology diagnostics market is expected to witness substantial growth throughout the forecast period, driven by increasing cancer prevalence, expanding precision medicine initiatives, rapid advancements in genomic technologies, and growing adoption of targeted therapies. Innovations in next-generation sequencing, liquid biopsy, digital PCR, artificial intelligence, and bioinformatics are transforming cancer diagnosis by enabling highly accurate molecular profiling and personalized treatment selection. Although high testing costs, regulatory challenges, reimbursement variability, and infrastructure limitations remain significant barriers, ongoing investment in cancer research and healthcare modernization is expected to support long-term market expansion. Molecular oncology diagnostics will continue to play a central role in precision oncology by enabling earlier diagnosis, optimized therapeutic decision-making, improved disease monitoring, and enhanced patient outcomes.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Molecular Oncology Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Overview of Molecular Oncology Diagnostics
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Cancer Burden and Diagnostic Demand Analysis
• 3.8 Molecular Biomarkers in Oncology
• 3.9 Epidemiology and Cancer Incidence Analysis
• 3.10 Diagnosed Patient Population Analysis
• 3.11 Oncology Testing Volume Analysis
• 3.12 Precision Oncology Treatment Landscape
• 3.13 Patient Journey and Molecular Testing Pathway
• 3.14 Unmet Clinical Needs

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 Technology Roadmap
• 6.6 Artificial Intelligence Integration in Molecular Oncology Diagnostics
• 6.7 Digital Pathology and Digital Health Integration

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Molecular Oncology Diagnostics Market Landscape Analysis

• 8.1 Analysis by Technology
• 8.2 Analysis by Biomarker Type
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Cancer Type
• 8.5 Analysis by Testing Methodology
• 8.6 Analysis by Clinical Application
• 8.7 Analysis by End User

9. Molecular Oncology Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Technology
  • 9.1.1 Polymerase Chain Reaction (PCR)
  • 9.1.2 Next-Generation Sequencing (NGS)
  • 9.1.3 Fluorescence In Situ Hybridization (FISH)
  • 9.1.4 Immunohistochemistry (IHC)
  • 9.1.5 Flow Cytometry
  • 9.1.6 Others
• 9.3 By Sample Type
  • 9.3.1 Tissue Biopsy
  • 9.3.2 Liquid Biopsy
    • 9.3.2.1 Whole Blood
    • 9.3.2.2 Plasma
    • 9.3.2.3 Serum
    • 9.3.2.4 Others
  • 9.3.3 Bone Marrow
  • 9.3.4 Other Body Fluids
• 9.4 By Cancer Type
  • 9.4.1 Breast Cancer
  • 9.4.2 Lung Cancer
  • 9.4.3 Colorectal Cancer
  • 9.4.4 Hematologic Malignancies
  • 9.4.5 Other Solid Tumors
• 9.5 By Application
  • 9.5.1 Clinical Diagnostics
    • 9.5.1.1 Cancer Screening
    • 9.5.1.2 Diagnosis
    • 9.5.1.3 Prognosis
    • 9.5.1.4 Companion Diagnostics
    • 9.5.1.5 Therapy Selection
    • 9.5.1.6 Others
  • 9.5.2 Research Use
    • 9.5.2.1 Drug Development
    • 9.5.2.2 Biomarket Discovery
    • 9.5.2.3 Clinical Trials Support
    • 9.5.2.4 Others
• 9.6 By End User
  • 9.6.1 Hospitals & Diagnostic Centers
  • 9.6.2 Diagnostic Laboratories
  • 9.6.3 Pharmaceutical and Biotechnology Companies
  • 9.6.4 Cancer Research Institutes
  • 9.6.5 Others

10. Molecular Oncology Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Molecular Oncology Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 Switzerland
• 11.10 Japan
• 11.11 China
• 11.12 India
• 11.13 South Korea
• 11.14 Australia
• 11.15 Brazil
• 11.16 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Illumina, Inc.
• 13.3 Thermo Fisher Scientific Inc.
• 13.4 Guardant Health Inc.
• 13.5 Tempus
• 13.6 Natera Inc.
• 13.7 NeoGenomics
• 13.8 Siemens AG
• 13.9 Danaher Corporation
• 13.10 Abbott Laboratories

14. Molecular Oncology Diagnostics Market Commercial Forecast Analysis

• 14.1 Next-Generation Sequencing-Based Oncology Diagnostics
• 14.2 PCR-Based Oncology Diagnostics
• 14.3 Liquid Biopsy Diagnostics
• 14.4 Companion Diagnostic Assays
• 14.5 Comprehensive Genomic Profiling Tests
• 14.6 Minimal Residual Disease (MRD) Diagnostics
• 14.7 Multi-Gene Cancer Panel Diagnostics

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends